Skip to content
Bored Studies
RecruitingPhase 2/Phase 3

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

Priovant Therapeutics, Inc. · NCT07532603

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2, Phase 3
Target enrollment
342
US sites recruiting
47
Study start
March 19, 2026
Record last updated
July 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Being studied: Oral Brepocitinib; Placebo

Conditions: Lichen Planopilaris

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age ≥ 18 years
  • Scalp biopsy consistent with LPP
  • Active and symptomatic LPP at screening and baseline-
  • Weight > 40 kg to \< 130 kg with BMI ≤ 45 kg/m2

Exclusion Criteria

  • History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
  • High risk of thrombosis or cardiovascular disease
  • High risk of herpes zoster
  • Active or recent infection

Recruiting US locations

Study contacts (from the official record)

  • Clinical Trial Administrator · (212) 634-9743 · clinicaltrials@priovant.com
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris (NCT07532603) | Bored Studies